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Methods. We conducted a multicenter prospective cohort study of 625 adult patients undergoing elective cardiac operations. All patients were taking statins and were grouped according to whether statins were continued or held in the 24 hours before operation. The primary outcome was AKI as defined by a doubling of serum creatinine or dialysis. The secondary outcome was the peak level of several kidney injury biomarkers. The results were adjusted for demographic and clinical factors.
Results. Continuing (vs holding) a statin before operation was not associated with a lower risk of AKI, as defined by a doubling of serum creatinine or dialysis (adjusted relative risk [RR] 1.09; 95% confidence interval [CI] 0.44, 2.70). However, continuing a statin was associated with a lower risk of elevation of the following AKI biomarkers: urine interleukin-18, urine neutrophil gelatinase-associated lipocalin, urine kidney injury molecule-1, and plasma neutrophil gelatinase-associated lipocalin (adjusted RR 0.34; 95% CI 0.18, 0.62), (adjusted RR 0.41; 95% CI 0.22, 0.76), (adjusted RR 0.37; 95% CI 0.20, 0.76), (adjusted RR 0.62; 95% CI 0.39, 0.98), respectively.
Conclusions. Statins may prevent kidney injury after cardiac operations, as evidenced by lower levels of kidney injury biomarkers. A cute kidney injury (AKI) is a common complication of cardiac operations associated with increased inhospital mortality and resource utilization and with poorer long-term survival and renal outcomes [1] [2] [3] . Unfortunately, despite multiple trials of prevention and treatment strategies, current therapy for AKI remains limited to supportive measures [4] . Increasing evidence, however, suggests that statins may be an effective preventative therapy. Statins possess antioxidant properties [5] , improve endothelial function [6] , and decrease inflammation [7] [8] [9] . Several animal studies have shown that statins are renoprotective when given before an ischemia-reperfusion type of injury [5] [6] [7] [8] . Unfortunately, the results in human studies are less consistent. Some observational studies have shown that statins decrease AKI and improve renal recovery when administered before or immediately after cardiac operations [10] [11] [12] [13] [14] [15] [16] , but other studies have not [17] [18] [19] . Many prior studies are retrospective, with limited data on the details of perioperative statin administration. As well, prior studies have all relied on changes in serum creatinine, a marker of AKI known to be insensitive and nonspecific [20] [21] [22] [23] . However, there are emerging data in support of AKI biomarkers, which may allow for a more accurate diagnosis of kidney injury in the setting of cardiac surgical procedures [24] [25] [26] .
To investigate the issue further, we conducted a secondary analysis of a large prospective cohort study. Our goal was to contrast AKI outcomes among individuals who had a statin continued or held before operation. We hypothesized that continuing a statin through cardiac surgical procedures would be associated with less AKI, as defined by serum creatinine and lower levels of kidney injury biomarkers.
Material and Methods

Study Population
This cohort is fully described elsewhere [25, 26] . In brief, we prospectively enrolled adults undergoing cardiac operations (coronary artery bypass grafting or valve procedures) who were at high risk for AKI at six academic medical centers in North America between July 2007 and December 2009. Participants with multiple surgical procedures could be enrolled only once. All participants provided written informed consent, and the study was approved by each institution's research ethics board. The reporting of this study follows the guidelines set out in the Strengthening the Reporting of Observational Studies in Epidemiology statement [27] .
Preoperative Statin Use
All included patients were taking a statin over the long term. Patients were grouped based on whether they were asked by their surgeon to continue or hold their statin in the 24 hours before operation.
Outcome Definitions
The primary outcome was the development of AKI as defined by the receipt of urgent dialysis or a doubling in serum creatinine from the baseline outpatient preoperative value during the entire hospital stay. In modern staging systems, this reflects Risk, Injury, Failure, Loss and End stage kidney disease (RIFLE) stage I or Acute Kidney Injury Network (AKIN) stage 2 AKI [28] . All preoperative creatinine values were measured within 2 months before operation. Preoperative and postoperative serum creatinine levels were measured in the same clinical laboratory at each center. Serum creatinine values were recorded for every patient throughout the hospital stay. The secondary outcome was an elevation of kidney injury biomarkers. As fully described elsewhere, we carefully collected urine and plasma specimens preoperatively and daily for up to 5 postoperative days [26] .
Kidney Injury Biomarker Measurements
We measured urine neutrophil gelatinase-associated lipocalin (NGAL) and urine interleukin-18 (IL-18) with the ARCHITECT assay (Abbott Diagnostics, Abbott Park, IL). We measured urine creatinine by the modified Jaffe reaction. We performed the measurements in two batches about 1 year apart. We measured plasma NGAL with the Triage NGAL immunoassay, in conjunction with the Triage Meter (Biosite Inc., San Diego, CA) in two batches 7 months apart. Urine NGAL, urine IL-18, and plasma NGAL concentrations are stable at À80 C for 2 years without any protease inhibitors, with a variability of 2% to 8% [29, 30] . The specifications and validation of the assays are fully described elsewhere [26] . We measured urine kidney injury molecule-1 (KIM-1) and urine liver-fatty acid binding protein (L-FABP) with the Sekisui Diagnostics LLC assay. The detection range for KIM-1 is 0.056 to 60 ng/mL; for L-FABP it is 0.057 to 1,500 ng/mL. The intraassay coefficient of variation is under 10% for both assays. Biomarkers were measured in duplicate, and an average of the two values was used. All urine albumin assays were measured by immunoturbidimetry on a Siemens Dimension Plus with HM clinical analyzer, according to the manufacturer's instructions.
Personnel performing the biomarker measurements were blinded to each patient's clinical information. All biomarkers were measured from frozen aliquots that did not undergo any additional freeze-thaw cycles. Repeated measurement of randomly selected samples between the batches confirmed high correlation without any assay drift for all the assays measured in two batches.
Variable Definitions
We collected preoperative characteristics, operative details, and postoperative complications using the definitions of the Society of Thoracic Surgeons [31] .We estimated preoperative glomerular filtration rate using the CKD-EPI equation [32] .
Analysis
We used a c 2 test or Fisher's exact test to compare dichotomous variables and a two-sample t test or Wilcoxon rank-sum test for continuous variables. We used a Poisson regression model to examine the association between continuing versus holding a statin and dichotomous outcomes [33] and linear regression for continuous biomarker levels (log-transformed). For the dichotomous biomarker outcome, as in prior studies, an elevated biomarker level was defined as a level in the highest quintile [25, 26] . The biomarker analyses were performed at two time points: (1) during the first 3 postoperative days and (2) within 6 hours after operation. In multivariable analysis, we adjusted for 12 important covariates that predict AKI in the setting of cardiac surgical procedures [34] : age (per year), gender, race, diabetes, type of operation, preoperative estimated glomerular filtration rate (<60, !60 mL/min•1.73 m 2 ), congestive heart failure, cardiac catheterization, preoperative urine albumin-to-creatinine ratio (<10, 10-30, >30 mg/g), and preoperative medication use (angiotensin converting enzyme inhibitor / angiotensin receptor blocker, diuretic, calcium channel blocker).
Results
The patient selection is presented in Figure 1 . Compared with those who had their statin held, patients who had their statin continued were more likely to have risk factors for AKI ( Table 2 ). AKI as defined by smaller increases in serum creatinine was also no different between the statin-held and statin-continued groups (Supplementary Table 3 ).
KIDNEY INJURY BIOMARKERS. The continuous biomarker levels for patients who had their statin continued versus held are presented in Table 2 . For all five biomarkers, patients who had their statin continued had significantly lower peak biomarker levels during the first 3 postoperative days than did those who had their statin held. The effect sizes ranged from 6% lower for albumin to 59% lower for IL-18. The biomarkers analyzed dichotomously are presented in Table 3 . Patients in the statin-continued group were less likely to have a peak level of urine IL-18, urine NGAL, urine KIM-1, and plasma NGAL in the upper quintile during the first 3 postoperative days. The peak levels of L-FABP and urine albumin did not differ significantly between the statin-continued and statin-held groups. The unadjusted results were similar.
SUPPLEMENTARY ANALYSES. The first postoperative biomarker levels are presented in Supplementary Tables 4 and 5 . When analyzed as a continuous variable, urine IL-18, urine NGAL, and plasma NGAL were significantly lower in the statin-continued group than in the statin-held group at 0 to 6 hours postoperatively (Supplementary Table 4 ). When analyzed dichotomously (top quintile results), patients in the statin-continued group were less likely to have elevated first postoperative biomarker levels of urine IL-18, urine NGAL, and plasma NGAL. The first postoperative biomarker levels of urine KIM-1, urine L-FABP, and urine albumin did not differ between the statin-continued and statin-held groups (Supplementary Table 5 ).
Comment
Our data suggest that statins may be an effective therapy for the prevention of kidney injury in the setting of cardiac surgical procedures. The hypothesis warrants testing in definitive randomized controlled trials.
The predominant contributors to AKI in the setting of cardiac surgical procedures are thought to be ischemia and inflammation induced by cardiopulmonary bypass [3] . It is therefore biologically plausible that statins, which possess antiinflammatory properties and improve endothelial function, could prevent AKI associated with cardiac surgical procedures [5] [6] [7] [8] [9] . To our knowledge, our study is the first to examine the association of statins with kidney injury biomarkers. As defined by serum creatinine level, AKI did not differ between the statin-continued and statin-held groups; however, this could have been the result of a lack of statistical power. The number of AKI events defined by a doubling in serum creatinine level or by dialysis was small, which could have been secondary to serum creatinine being an insensitive and nonspecific marker for AKI [20] [21] [22] [23] . Haase and colleagues [35] pooled the data from ten studies (>2,000 critically ill patients) and found that almost 20% of included patients had elevated levels of NGAL with normal serum creatinine. These patients were labeled as likely having subclinical AKI. The majority of patients in our study would fall into this category. The label of subclinical AKI suggests that it is not a clinically meaningful outcome, but patients in the study by Haase and colleagues [35] were found to have a higher rate of adverse outcomes. As well, a recent study found that patients who had elevated urine NGAL or elevated urine KIM-1 with normal serum creatinine on admission to the hospital had a higher risk of requiring dialysis or dying during their hospital stay [36] . Another recent study found that elevated urinary NGAL was associated with higher 1-year mortality [37] . Taken together, these studies provide compelling evidence that elevated levels of kidney injury biomarkers are predictive of adverse shortterm and long-term outcomes.
Strengths and Limitations
Our study has several strengths. It was conducted prospectively, allowing for accurate data collection on preoperative statin use; it used rigorous complete specimen collection; it was performed under standardized conditions in consecutive patients undergoing cardiac operations; and it included multiple centers across the United States and Canada. As well, dividing patients into statinheld and statin-continued groups, as opposed to prescribing or not prescribing statin for a patient, is likely most representative of how a statin AKI intervention trial could be conducted, given that most patients preparing to undergo a cardiac operation are already taking a statin. Also, the decision to hold a statin is predominantly the surgeon's preference; therefore, an observational study comparing statin-held with statin-continued groups may be less prone to confounding by indication than the alternative design of preoperative statin yes versus no. Our study is limited by a small number of renal events defined by serum creatinine level or dialysis. Unfortunately, owing to the sample size, we were also unable to account for center effects in our analysis, and we did not quantify or account for statin use after the operation. We also did not account for dose or type of statin, which could have affected the results, given the evidence to suggest that higherpotency statins are associated with less perioperative AKI than are lower-potency statins [38] . As well, the allocation of preoperative statin holding was nonrandom. Because of the observational nature of our study, the protective association seen between preoperative statin administration and elevation of AKI biomarkers may not be causal. However, patients in the statin-continued group had a greater number of risk factors for AKI, such as chronic kidney disease and use of cardiopulmonary bypass. One might expect that residual confounding should, if anything, result in more AKI in the statin-continued group.
Future Directions
A proposed reason for the failure of prior interventional trials is their reliance on serum creatinine and thus the inability to accurately diagnose AKI in its early stages. Also, trials that define AKI solely by a significant rise in serum creatinine or dialysis require thousands of patients for adequate statistical power. As a result, promising therapies may fail to undergo definitive testing if small, underpowered trials show no benefit of the intervention. As demonstrated in our proof-of-concept study, AKI biomarker(s) have a better signal-to-variability ratio and may decrease the required sample size to detect a signal of AKI. In this regard, both increases in serum creatinine and elevated biomarker levels are surrogate outcomes. Their utility therefore lies in identifying promising interventions worthy of definitive testing in large, expensive, multicenter randomized controlled trials with adequate statistical power to examine intervention effects on outcomes that matter most to patients and their health care providers. a Elevated peak biomarker levels were defined as the 5 th quintile: (urine IL-18 >201 pg/mL, urine NGAL >156 ng/mL, urine KIM-1 >15.8 ng/mL, plasma NGAL >307 ng/mL, urine L-FABP >199 ng/mL, urine albumin >121.6mg/L). Peak biomarker levels were defined as the highest biomarker value in the first 3 postoperative days.
b Adjusted for age, gender, race, diabetes, type of operation (CABG and valve vs CABG or valve), preoperative eGFR (<60, !60), congestive heart failure, cardiac catheterization, preoperative urine albumin-to-creatinine ratio (<10, 10-30, >30), preoperative ACEi/ARB, preoperative diuretic (yes/no), preoperative calcium channel blocker (yes/no). 
INVITED COMMENTARY
Acute kidney injury (AKI) after cardiac operations typically involves the tubular cells, which are highly sensitive to decreases in oxygen delivery during cardiopulmonary bypass [1] . Blood flows first through the glomeruli-rich renal cortex, where it is partially desaturated, and then to the medulla where the tubules reside. AKI is multifactorial and is correlated with poorer short-and long-term survival [2] . The combination of oxygen depletion and the systemic inflammatory response associated with cardiopulmonary bypass are central features [1] . The vulnerability of the renal medulla to oxygen delivery and inflammation provides us with a signal as to how well these issues were addressed preoperatively and intraoperatively. The analysis by Molnar and colleagues [3] lends support to the hypothesis that AKI may be ameliorated by the antiinflammatory effect of statins, adding to the evidence supporting the use of preoperative statins in cardiac operations [4] . By comparing the practice of holding statins before surgical procedures or continuing them, the authors found no difference in the primary outcome of
